2024-09-08 - Analysis Report
## VRTX Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals, Inc. (VRTX) is a biotechnology company focused on the development and commercialization of therapies for patients with serious and life-threatening diseases. 

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** VRTX has a cumulative return of 106.11%, compared to 81.34% for the S&P 500 (VOO). 
* **Outperformance:** VRTX has outperformed the S&P 500 by 24.77%. This places VRTX at the 80.81 percentile of its historical outperformance range, indicating a strong relative performance. 

**2. Recent Price Movement:**

* **Closing Price:** $468.0
* **Moving Averages:**
    * 5-day: $477.35
    * 20-day: $478.84
    * 60-day: $481.33

The stock price is currently below all three moving averages, suggesting a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 43.6, indicating a neutral to slightly oversold market condition.
* **PPO:** -0.31, indicating a bearish trend.
* **Delta_Previous_Relative_Divergence:** -2.06, suggesting a short-term downward trend.
* **Expected Return:** 9.28%, representing the potential 5-year return based on current investment.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

* The most recent earnings report showed a significant decline in EPS (-13.92) compared to the previous quarter, which may be a cause for concern. 
* However, revenue remains relatively consistent, indicating continued growth in the company's core business.

**Overall Analysis:**

VRTX has demonstrated strong relative performance compared to the broader market, with a cumulative return exceeding the S&P 500. While recent price action and technical indicators suggest a short-term bearish trend, the company's consistent revenue growth provides a potential positive outlook. The recent earnings miss requires further investigation and analysis of the contributing factors. 

The expected 5-year return of 9.28% is an encouraging indicator, but investors should carefully consider the current market conditions and recent earnings performance before making any investment decisions. Further due diligence is recommended, including a deeper dive into the company's pipeline and competitive landscape. 
